CR-0305

About Coeurative

Coeurative is a private, preclinical biotech focused on a significant unmet need in cardiovascular medicine: effective treatment for angina pectoris, especially in patients with INOCA and refractory angina where current therapies fail. Its lead asset, CR-0305, employs a proprietary dual-mechanism approach that has demonstrated 23x greater vasodilatory potency than the standard-of-care isosorbide mononitrate in ex vivo studies, alongside a favorable safety profile. The company is advancing IND-enabling studies with plans to initiate Phase 1 trials in 2028, targeting a multi-billion dollar global market opportunity. Coeurative represents a high-potential, early-stage venture aiming to deliver a curative strategy for coronary artery disease.

Therapeutic Areas